Cargando…
pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4(CRBN) ubiquitin ligase
Thalidomide and its derivatives lenalidomide and pomalidomide (IMiDs) are effective treatments of haematologic malignancies. It was shown that IMiDs impart gain-of-function properties to the CUL4-RBX1-DDB1-CRBN (CRL4(CRBN)) ubiquitin ligase that enable binding, ubiquitination and degradation of key...
Autores principales: | An, Jian, Ponthier, Charles M., Sack, Ragna, Seebacher, Jan, Stadler, Michael B., Donovan, Katherine A., Fischer, Eric S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458144/ https://www.ncbi.nlm.nih.gov/pubmed/28530236 http://dx.doi.org/10.1038/ncomms15398 |
Ejemplares similares
-
The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma
por: Heider, Michael, et al.
Publicado: (2021) -
CRL4(CRBN) E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma
por: Barankiewicz, Joanna, et al.
Publicado: (2022) -
Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy
por: Thakurta, A, et al.
Publicado: (2014) -
Regulation of AMPK Activity by CRBN Is Independent of the Thalidomide-CRL4(CRBN) Protein Degradation Axis
por: Yang, Seung-Joo, et al.
Publicado: (2021) -
IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?
por: Suzuki, Kazuhito, et al.
Publicado: (2023)